Navigation Links
EnzySurge, Maker of DermaStream(TM), Establishes a US Office in the Virginia Biotech Commercialization Center
Date:4/2/2008

RICHMOND, Virginia and ROSH HAAYIN, Israel, April 2 /PRNewswire/ -- The Virginia Biosciences Commercialization Center (VBCC) recently announced the newest company to establish their U.S. office at the Virginia BioTechnology Research Park as a member of the VBCC program, EnzySurge, an Israeli bioscience company focused on chronic wound management.

"EnzySurge has developed DermaStream(TM) based on its proprietary Continuous Streaming Therapy(TM) (CST) technology. DermaStream(TM) is a comprehensive yet versatile treatment for hard-to-heal chronic wounds throughout the debridement, regeneration and closure phases, designed for hospitals, clinics and home treatment" stated Donna Edmonds, executive director of the VBCC. "We're very excited to support the introduction of this innovative product line to the U.S. market. "Pressure, venous and diabetic wounds are an increasing problem in the United States, with more than 6 million cases reported annually. Each year, more than 2.3 million Americans are treated for diabetes-related skin ulcers and more than 100,000 amputations are performed on diabetic patients due to non-healing wounds."

Treatment of chronic wounds is a costly, long, multi-step process that often requires hospitalization, and is extremely uncomfortable for the patient. The process involves debriding the wound, surgically removing unhealthy tissue, flushing the wound with anti-microbial products and keeping the open wound clear of infection to promote tissue regeneration and hopefully lead to wound closure.

The DermaStream device continuously streams fresh highly active solutions in an isolated, optimally receptive and bacteria-controlled wound environment, thereby provides faster, more effective and comprehensive chronic wound treatment - from wound debridement, through regeneration to closure

"We're dedicated to developing innovative solutions that expedite wound healing and improve patients' quality of lives," stated Amir Shiner, CEO of EnzySurge. "The VBCC program brings us closer to getting a much needed medical tool in the hands of the clinicians who can use them."

About the Park

The Virginia BioTechnology Research Park is currently home to a unique mix of more than 55 public and private bioscience companies, research institutes affiliated with the VCU Medical Center and major state and national medical laboratories. These companies are housed in nine buildings totaling more than 1.1 million square feet of space, representing an employee base that exceeds 2,000. The VBDC is the Virginia BioTechnology Research Park's business assistance program located in its 27,000-square-foot incubator. Since opening in 1995, 63 companies have started in the Park's incubator facility; 31 of which have graduated into larger spaces in the Park or greater Richmond community. The Park's Commercialization Center has been created to take incubator graduates through commercialization to M&A or IPO, giving the Park's tenants full-scale business assistance. The Commercialization Center is now the home of eight companies from the Israeli life science community and continues to expand its resource base. It has created alliances with leading incubators in Israel. To date, the Park has graduated three companies that are now publicly traded.

About EnzySurge

EnzySurge Ltd. is a developer and provider of innovative solutions for the treatment and management of chronic wounds. EnzySurge's patented and FDA cleared DermaStream(TM) - is an innovative wound care platform, which together with a set of advanced bio-active solutions, forms the basis for the new and unique wound treatment modality - Continuous Streaming Therapy(TM) (CST). Dermastream(TM) enables a new, controlled chronic wound environment that ensures a continuous fresh supply of therapeutic solutions to the wound. DermaStream(TM) is designed to deliver effective, affordable and easy-to-use wound treatment throughout all phases of chronic wound life cycle from debridement, through regeneration to wound closure. DermaStream(TM) was designed for use in hospitals, clinics and for home care.

EnzySurge is committed to the development and delivery of innovative solutions that improve the quality of life of chronic-wound patients, by shortening healing time and reducing treatment costs. For more information, visit http://www.dermastream.com

Contact

Nicky Colomb

Virginia BioTechnology Research Park

Phone: +1-804-828-6884

E-mail: ncolomb@vabiotech.com

Web site: http://www.vabiotech.com

Boaz Gruener

Director of Marketing and Business Development

Phone: +972-54-4563608

Email: boazg@enzysurge.com


'/>"/>
SOURCE The Virginia Biosciences Commercialization Center andEnzySurge Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
2. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
3. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
4. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
5. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
6. BioMarin to Present at the BioCentury NewsMakers Conference
7. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
8. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
9. Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
10. BSP Pharma Inc., Makers of FlexNow(TM) Joint Formula Sign Distribution Deal with Vitamin Shoppe and GNC
11. Bioscience Group Warns Policymakers Against Complacency
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... , ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension ... are higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... bottom of the cuvette holder. , FireflySci has developed several Agilent flow cell ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... the launch of the Supplyframe Design Lab . Located in Pasadena, Calif., ... the future of how hardware projects are designed, built and brought to market. ...
Breaking Biology Technology:
(Date:5/20/2016)... 20, 2016  VoiceIt is excited to announce ... By working together, VoiceIt and VoicePass ... and VoicePass take slightly different approaches to voice ... security and usability. ... new partnership. "This marketing and technology ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
Breaking Biology News(10 mins):